文献速递泌尿生殖与妇科肿瘤放疗

ISUP前列腺癌分级分组在剂量递增外照射放疗中的验证

Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation.
PubMed 文献 · Radiother Oncol · 2021-06-24

本研究在四家机构纳入2205例接受图像引导、剂量递增(≥78 Gy)外照射放疗的局限前列腺癌患者,中位随访5.6年。结果显示ISUP分级分组未能获得验证:1-4级组间生化失败风险无统计学差异,仅5级组预后显著更差;Harrell C指数更支持一种新的三组模型。

要点

  • ISUP 1-4级组间生化失败风险无统计学差异,仅5级组显著更差。
  • 7年生化失败率:1-5级分别为9.3%、10.4%、13.2%、12.4%、23.4%。
  • 新三组模型(6与3+4=7 vs 4+3=7与8 vs 9与10)预测优于ISUP分组。

核心结论

  • ISUP分级分组在当代剂量递增图像引导放疗队列中未获验证。
  • 1-4级组间生化失败风险无统计学差异,5级组预后显著更差。
  • 新三组模型对生化结局的预测优于ISUP分级分组。

研究设计与样本

  • 多机构回顾性队列,纳入2205例局限前列腺癌患者。
  • 治疗为图像引导、剂量递增(≥78 Gy)外照射放疗。
  • 主要终点为生化失败时间,中位随访5.6年。
  • 采用Harrell C指数比较ISUP分组与其他分级分层。

主要发现

  • 1-5级组7年生化失败率分别为9.3%、10.4%、13.2%、12.4%、23.4%。
  • 多因素分析中,相对2级,1-5级生化失败风险比为1.19、1.00、1.10、1.05、2.10。
  • 仅5级组风险比具统计学显著性。
  • Harrell C指数更支持新三组模型而非ISUP分级分组。

关键数值与推荐

  • 新三组模型分组为:Gleason 6与3+4=7;4+3=7与8;9与10。
  • 剂量递增定义为≥78 Gy。
  • ISUP 1-5级7年生化失败率分别为9.3%、10.4%、13.2%、12.4%、23.4%。

临床怎么用

  • 对接受剂量递增放疗患者,ISUP 1-4级间风险区分有限,应谨慎单独用于预后分层。
  • ISUP 5级提示显著更差生化结局,可考虑强化治疗或密切随访。
  • 新三组模型可能更适用于现代放疗患者的风险分层,但需外部验证。

局限性

  • 为回顾性多机构队列研究,可能存在选择偏倚。
  • 中位随访5.6年,长期结局尚不明确。
  • 新三组模型需进一步验证后方可用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The five grade group system has been validated for men treated with radical prostatectomy. However, the prognostic value for men treated with radiation therapy is uncertain, with prior studies utilising old techniques and doses. We aimed to validate the International Society of Urological Pathology (ISUP) groupings for men treated with contemporary radiation therapy. METHODS: Men with localised prostate cancer treated with image-guided, dose-escalated (≥78 Gy) external beam radiation were identified across four institutions. Primary outcome was time to biochemical failure. Harrell's C index assessed performance of the ISUP system against other grading stratifications. RESULTS: 2205 men were included, withmedian follow-up of 5.6 years. Seven-year actuarial rates of biochemical failure for grade groups 1-5 were 9.3%, 10.4%, 13.2%, 12.4% and 23.4%. On multivariate analysis, hazard ratios for biochemical failure were1.19, 1.00, 1.10, 1.05 and 2.10 for grade groups 1-5, relative to 2. P values were only significant for grade group 5. Harrell's C index favoured an alternative three group model (comprising Gleason scores [6 and 3 + 4 = 7] vs [4 + 3 = 7 and 8] vs [9 and 10]) over ISUP grade groups. CONCLUSIONS: The ISUP grade groups were not validated in a contemporary cohort treated with dose-escalated, image-guided radiation therapy. Grade groups 1-4 were not statistically different from each other; however, grade group 5 had a significantly worse prognosis. We identified a new three group model that better predicted biochemical outcomes. Further work is requiredto validate optimal groupings for modern radiation therapy and investigate the contrasting prognostic capability of grade groups in surgical and radiation therapy patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Toby J, Eade T, Hruby G, et al. Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. Radiother Oncol. 2021. PMID: 34171454. doi:10.1016/j.radonc.2021.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。